|
 |
European BioPharmaceutical Review
|
| In his most recent Budget, the Chancellor announced the R&D tax credit for larger companies, complementing the R&D tax credit for small and medium-sized companies introduced in Budget 2000. Together the two credits will represent £500 million a year in additional Government support for business R&D investment in the UK. This level of commitment reflects the Government's determination to increase the level of R&D investment by UK industry. As Figure 1 shows, business R&D intensity in the UK does not fare well with comparable economies.Figure 1 shows the overall average business R&D intensity in the UK, but the picture varies from sector to sector. At 14.8 per cent of sales (1), R&D investment by the UK pharmaceutical industry is competitive by international standards - although recent years have seen a trend for UK-owned groups to undertake an increasing proportion of their R&D outside the UK, and we estimate a decline in the UK share of worldwide pharmaceutical R&D from 11 per cent to 9 per cent (2). |
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
Small Scale Biomanufacturing – clinical trials, cell & gene therapies
18 September 2008, Clifton Pavilion, Bristol Zoo Gardens, Bristol
This one day conference, sponsored by bioProcessUK and organised by BioApproaches South West, will cover key, important topics relating to small scale GMP biomanufacturing.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Product Development Group, Inc
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >> |
|
 |
